Medicines labeled for the same conditions
Alternatives to adalimumab-ryvk
12 other medicines are given the same way (subcutaneous) and in the same FDA class as adalimumab-ryvk or labeled mainly for the same use (psoriasis); the others include 3 tumor necrosis factor blockers, 2 interleukin-23 antagonists and 2 interleukin-17a antagonists (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as adalimumab-ryvk?
Psoriasis lists all 38 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Adalimumab-ryvk | this medicine | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | Yes | A presentation being discontinued |
| Adalimumabtumor necrosis factor blocker | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry |
| Methotrexatefolate analog metabolic inhibitor | Rheumatoid arthritis, Psoriasis | none listed | $289.37 per mL 25 mg/0.5 mL autoinj | Yes | In shortage |
| Etanercepttumor necrosis factor blocker | Rheumatoid arthritis, Psoriasis | none listed | $2,084.14 per mL 25 mg/0.5 mL syringe | Yes | No current entry |
| Risankizumabinterleukin-23 antagonist | Crohn's disease and ulcerative colitis, Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No | No current entry |
| Bimekizumab | Psoriasis | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No | No current entry |
| Ixekizumabinterleukin-17a antagonist | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No | No current entry |
| Secukinumabinterleukin-17a antagonist | Psoriasis | none listed | $3,946.35 per mL 300 mg dose/2 pens (150 mg/pen) | No | No current entry |
| Spesolimabinterleukin-36 receptor antagonist | Psoriasis | none listed | n/a | No | No current entry |
| Certolizumabtumor necrosis factor blocker | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry |
| Adalimumab-aacf | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | n/a | Yes | No current entry |
| Brodalumabinterleukin-17 receptor a antagonist | Psoriasis | none listed | n/a | Yes | No current entry |
| Tildrakizumabinterleukin-23 antagonist | Psoriasis | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Adalimumab-ryvk: the full record
- label, generics, price, shortages, recalls